Patients now have access to this next-generation BPH treatment providing clinically-proven, immediate and lasting results
(Perth Amboy, NJ – May 10, 2024) – Hackensack Meridian Raritan Bay Medical Center announced today that it is the first hospital in the Hackensack Meridian Health network to offer patients the Optilume® BPH Catheter System for the treatment of Benign Prostatic Hyperplasia (BPH). Typically administered as an outpatient procedure, Optilume BPH is a new, safe and effective minimally-invasive procedure that provides patients with immediate improvement in urinary symptoms and quality of life.
As men age, it’s common to encounter prostate enlargement, leading to a condition known as BPH. In fact, BPH affects 70% of men 60-69 years of age and 80% of those 70 years of age or older. The prostate surrounds the tube responsible for transporting urine and semen, known as the urethra. With BPH, as the prostate grows larger, it exerts pressure on the urethra, potentially causing interruptions in the natural flow of urine.
“We’re excited to bring the latest advancements in BPH treatment to our patients. As the first to offer Optilume BPH in our network, we’re committed to providing our community with access to the most innovative and effective care,” said Patricia Carroll, FACHE, president, chief hospital executive.
The FDA-approved Optilume BPH Catheter System revolutionizes the treatment paradigm by providing symptom relief for men experiencing BPH induced lower urinary tract symptoms, including frequent trips to the bathroom, day and night; weak, slow or intermittent flow; urgent need to pee; and inability to fully empty bladder.
Optilume BPH is a drug-coated balloon that is inserted into the urethra via a telescopic camera, to the prostate. Once in the prostate, the balloon expands creating an opening, and releases the safe and proven drug paclitaxel, into the open prostate. When the drug coating is fully released, the balloon is deflated and removed. The purpose of the drug is to keep the prostate open, restoring the flow of urine.
“I am excited about Optilume BPH to help men manage their symptoms and improve their quality of life. In my experience, patients who have used Optilume BPH have reported significant improvements in their symptoms, including reduced urinary urgency and frequency, improved urinary flow, and better sleep. I believe that Optilume BPH is a valuable new treatment option for men with BPH,” said Neil Sherman, MD, urologist, Raritan Bay Medical Center.
Highlights of the Optilume BPH Catheter System include:
Clinical studies show Optilume BPH is safe and effective
Symptom relief
Minimal catheter time post-procedure
No impact on sexual function
Quick recovery
In-office/outpatient procedure
No cutting, heating, burning, lasering, steaming, or implantation
About Hackensack Meridian Raritan Bay Medical Center and Old Bridge Medical Center:
For more than 100 years, Hackensack Meridian Raritan Bay Medical Center and Old Bridge Medical Center have provided a full continuum of health care services to residents of Central Jersey. Raritan Bay Medical Center is one of less than one percent of hospitals in the world to achieve Magnet Recognition, the “Gold Standard” for nursing practice, quality, and safety in patient care, four times. In 2019, U.S. News & World Report ranked Raritan Bay Medical Center as high performing in Orthopedics, Nephrology, COPD and Heart Failure.
The medical center is a New Jersey state designated Primary Stroke Center and recipient of the American Heart Association/American Stroke Association’s Get With The Guidelines® Target: Stroke Honor Roll Elite Gold Plus Quality Achievement Award, recognizing optimal treatment of stroke patients. Raritan Bay is also a recipient of the Joint Commission’s Gold Seal of Approval and the AHA’s Heart Check Mark for Advanced Certification for Primary Stroke Centers and the AHA’s Mission: Lifeline® EMS Gold Plus Performance Achievement Award recognizing high-quality care of patients experiencing a severe heart attack.
For more information, visit www.rbmc.org.
About Optilume BPH
The Optilume® BPH Catheter System, a new FDA-approved drug-coated balloon technology, provides a minimally invasive treatment option for men suffering from benign prostatic hyperplasia (BPH). The drug-coated balloon technology creates a paradigm change from methods currently used by urologists to treat these conditions. Optilume is owned by Laborie, a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology & Neonatal Health. For more information visit www.laborie.com or www.optilume.com/bph.
SOURCE; HMH Raritan Bay Medical Center
